US Stock Market Move | ImmunityBio (IBRX.US) continues to rise by over 13% in pre-market trading, and has already surged by 178% this year.

On Tuesday, ImmunityBio (IBRX.US) continued to rise by more than 13% before the market opened, surging 178% so far this year and now trading at $6.31. In terms of news, ImmunityBio stated that the Food and Drug Administration (FDA) is seeking more information related to the company's supplemental biologics license application, which involves the use of Anktiva in combination with BCG for the treatment of non-muscle invasive bladder cancer in patients with papillary tumors. The FDA has recommended that the company provide certain additional information to support a potential resubmission of the application initially submitted last year for the indication of papillary tumors. ImmunityBio stated that it will submit the necessary information to the FDA within the next 30 days. According to the company, the additional information does not involve initiating or designing new clinical trials.